AbbVie : ABBV

All AbbVie Articles

565 Articles

Paul Ausick | May 5, 2014 at 11:20 AM EDT

Why Target Shares Fell Rather Than Rose on CEO Firing

Shares of Target took a hit of around 3% Monday morning following the resignation/firing of CEO Gregg Steinhafel. The interim…

Jon C. Ogg | Mar 27, 2014 at 9:15 AM EDT

Baxter Split-Up, a Page From Abbott’s Playbook

Baxter International is taking an activist investor role of its own. The health care company has announced that it is…

Trey Thoelcke | Mar 14, 2014 at 8:50 AM EDT

Jefferies’ Cheapest Health Care Stocks to Buy

In a new report out from Jefferies, the analysts posted a complete list of the cheapest, on a P/E basis,…

Trey Thoelcke | Mar 4, 2014 at 8:50 AM EST

Merrill Lynch’s Top Health Care Stocks to Buy Now

Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to…

Jon C. Ogg | Feb 8, 2014 at 8:30 AM EST

Five Quantitative Analyst Stocks With Limited Emerging Markets Exposure

In Deutsche Bank's monthly quant view research piece, the firm looks for strategies that investors can implement to limit their…

Jon C. Ogg | Dec 30, 2013 at 11:30 AM EST

Many Key Changes to Goldman Sachs Conviction Buy List for 2014

If one firm can create interest around a stock, it is Goldman Sachs. Investors have followed its Conviction Buy List…

Jon C. Ogg | Dec 7, 2013 at 8:01 AM EST

Goldman Sachs Makes Major Conviction Buy List Changes for 2014

GS.COMIt is that time of year when investors start positioning their portfolios for the year ahead. 24/7 Wall St. reviews…

Jon C. Ogg | Dec 3, 2013 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Tuesday, December 3, 2013.…

Jon C. Ogg | Oct 29, 2013 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Apple, BBVA, Kors, PotBelly and More

Jon OggWe are in the thick of earnings season, a deal was made in D.C. and stocks are challenging new…

Jon C. Ogg | Oct 16, 2013 at 11:20 AM EDT

New IPO ETF Certain to Gain Traction, More IPO ETF Competition

ThinkstockThe saying is that if there is a trading strategy, then there is an ETF strategy for that as well.…

Jon C. Ogg | Oct 9, 2013 at 8:15 AM EDT

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

ThinkstockThe drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week’s government shutdown…

Jon C. Ogg | Oct 2, 2013 at 12:25 PM EDT

Spin-Offs Back in Vogue: Six Must-Watch Special Situations

ThinkstockWhen the markets go through periods of great gains, it is not uncommon to see companies start to take more…

Lee Jackson | Sep 16, 2013 at 8:45 AM EDT

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the…

Jon C. Ogg | Jun 6, 2013 at 8:00 AM EDT

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

ThinkstockAs the pharmaceuticals industry looks toward restructuring and separation of undervalued assets, Jefferies analysts have prepared a highly proprietary sum…

Jon C. Ogg | May 14, 2013 at 7:50 AM EDT

Merrill Lynch Large Cap Pharmaceutical Stocks to Buy

ThinkstockOne of the downsides to a market that seems to go up every day is knowing what stocks to own…

1 … 35 36 37 38

AbbVie : ABBV

All AbbVie Articles

Why Target Shares Fell Rather Than Rose on CEO Firing

Baxter Split-Up, a Page From Abbott’s Playbook

Jefferies’ Cheapest Health Care Stocks to Buy

Merrill Lynch’s Top Health Care Stocks to Buy Now

Five Quantitative Analyst Stocks With Limited Emerging Markets Exposure

Many Key Changes to Goldman Sachs Conviction Buy List for 2014

Goldman Sachs Makes Major Conviction Buy List Changes for 2014

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

Top Analyst Upgrades and Downgrades: Apple, BBVA, Kors, PotBelly and More

New IPO ETF Certain to Gain Traction, More IPO ETF Competition

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

Spin-Offs Back in Vogue: Six Must-Watch Special Situations

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

Merrill Lynch Large Cap Pharmaceutical Stocks to Buy

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

AbbVie : ABBV

All AbbVie Articles

Why Target Shares Fell Rather Than Rose on CEO Firing

Baxter Split-Up, a Page From Abbott’s Playbook

Jefferies’ Cheapest Health Care Stocks to Buy

Merrill Lynch’s Top Health Care Stocks to Buy Now

Five Quantitative Analyst Stocks With Limited Emerging Markets Exposure

Many Key Changes to Goldman Sachs Conviction Buy List for 2014

Goldman Sachs Makes Major Conviction Buy List Changes for 2014

Top Analyst Upgrades and Downgrades: Apple, 3D Systems, Micron, Tesla and More

Top Analyst Upgrades and Downgrades: Apple, BBVA, Kors, PotBelly and More

New IPO ETF Certain to Gain Traction, More IPO ETF Competition

Credit Suisse Major Drug Stocks to Buy for Great Gains Ahead

Spin-Offs Back in Vogue: Six Must-Watch Special Situations

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

Jefferies Raises Price Targets on Pharmaceutical Stocks to Buy

Merrill Lynch Large Cap Pharmaceutical Stocks to Buy

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026